<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03827161</url>
  </required_header>
  <id_info>
    <org_study_id>RG1001578</org_study_id>
    <secondary_id>NCI-2018-02647</secondary_id>
    <nct_id>NCT03827161</nct_id>
  </id_info>
  <brief_title>Glucosamine and Chondroitin in Preventing Inflammation in Overweight Patients</brief_title>
  <official_title>GLANCE 2 - Glucosamine and Chondroitin (G&amp;C) Effects Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies glucosamine and chondroitin in preventing inflammation in overweight
      patients. Chronic inflammation contributes to cancer formation, and biomarkers of
      inflammation have been associated with cancer risk. Glucosamine and chondroitin may prevent
      inflammation and this trial may help identify the bacteria that help process them in the gut.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of glucosamine sulfate/chondroitin sulfate tablet (G&amp;C) on gut microbial community modulation</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>shifts in the bacterial communities within person based on clustering of operational taxonomic units (OTU) at 97% utilizing principal coordinate analysis [PCOA]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of G&amp;C on serum C-reactive protein (CRP)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>evaluated using a generalized estimating equation which accounts for variation due to repeated measures within an individual</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Healthy Subject</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Arm I (glucosamine sulfate/chondroitin sulfate tablet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucosamine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (glucosamine sulfate/chondroitin sulfate tablet)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Individuals from the Greater Seattle area who are overweight (body mass index [BMI] of
        25-32.5 kg/m^2)

        Exclusion Criteria:

          -  Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or
             inflammatory conditions (including autoimmune and inflammatory diseases)

          -  Pregnancy or lactation

          -  Currently on a weight-loss diet

          -  BMI (body mass index) &lt; 25 or &gt; 32.5 kg/m^2

          -  Alcohol intake of greater than 2 drinks/day (2 drinks being equivalent to 720 ml beer,
             240 ml wine or 90 ml spirits)

          -  Current use of prescription or over-the-counter medications other than oral
             contraceptives and hormone secreting intrauterine device (IUD)s, multivitamin pills or
             infrequent use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), or use of
             aspirin or NSAIDs more than 2 days per week

          -  Abnormal renal, liver or metabolic test

          -  Inability to swallow pills

          -  Known allergy to shellfish

          -  Not willing to take pills made from shellfish or animal sources

          -  Intention to relocate out of study area within next 2 months

          -  Any antibiotic use in the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Lampe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

